A double-blind, randomized study to evaluate the efficacy and safety of lapaquistat acetate [lapaquistat] 50 mg vs placebo in subjects with hypercholesterolemia, with an optional open-label extension.

Trial Profile

A double-blind, randomized study to evaluate the efficacy and safety of lapaquistat acetate [lapaquistat] 50 mg vs placebo in subjects with hypercholesterolemia, with an optional open-label extension.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Lapaquistat (Primary)
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Nov 2012 Planned number of patients changed from 650 to 660.
    • 28 Mar 2008 Status changed from initiated to discontinued. According to a Takeda media release, development of lapaquistat is being discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top